Digestive Diseases and Sciences

, Volume 42, Issue 9, pp 1853–1858 | Cite as

Increased Esophageal Chemoreceptor Sensitivity to Acid in Patients After Successful Reversal of Barrett's Esophagus

  • Ronnie Fass
  • John M. Yalam
  • Lisa Camargo
  • Cindy Johnson
  • Harinder S. Garewal
  • Richard E. Sampliner


When compared to patients with erosiveesophagitis, patients with Barrett's esophagus havedemonstrated reduced chemo- and mechanoreceptorsensitivity to acid infusion and balloon distension,respectively. However, anecdotal clinical experiencesuggested an increase in symptom perception in patientsafter successful elimination of Barrett's epithelium,using multipolar electrocoagulation (MPEC) and high-dose proton pump inhibitor (PPI). To determineperception thresholds to acid infusion, we evaluatedeight consecutive patients after a series of MPECtreatments resulted in complete elimination of Barrett's mucosa and compared them to 10 age-matchedpatients with nonreversed Barrett's esophagus and 10patients with symptomatic, endoscopy-documented erosiveesophagitis (Hetzel-Dent grade 2 or greater).Chemosensitivity was determined by a modified acid perfusiontest, where acid perception thresholds were quantifiedby the lag time to initial typical symptom perception,sensory intensity rating, and an acid perfusion sensory score (APSS). While patients aftersuccessful elimination of Barrett's esophagus hadsimilar sensory intensity ratings and APSS as patientswith erosive esophagitis, the lag times differedsignificantly between the groups, and both groups hadsignificantly higher sensory intensity ratings and APSSthan patients with nonreversed Barrett's esophagus. Inconclusion, patients after complete reversal ofBarrett's mucosa are unexpectedly as sensitive to acid assymptomatic patients with erosive esophagitis.



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, et al: Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 344:1533–1536, 1994Google Scholar
  2. 2.
    Pera M, Cameron AJ, Trastek VJ, Carpenter HA, et al: Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104:510–513, 1993Google Scholar
  3. 3.
    Gore S, Healey CJ, Sutton R, Eyre-Brook IA, et al: Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 7:632–638, 1993Google Scholar
  4. 4.
    McArdle JE, Lewin KJ, Randall G, Weinstein W: Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol 23:479–482, 1992Google Scholar
  5. 5.
    Gossner L, Sroka R, Stolte M, Seitz G, et al: Barrett's esophagus with severe dysplasia and/or superficial cancer: Initial results of photodynamic therapy using 5-aminolaevolinic acid. Gastrointest Oncol 110:A521, 1996Google Scholar
  6. 6.
    Sampliner RE, Hixson LJ, Fennerty MB, Garewal HS: Regression of Barrett's esophagus by laser ablation in an antacid environment. Dig Dis Sci 38:365–368, 1993Google Scholar
  7. 7.
    Berenson MM, Johnson TD, Markowitz NR, et al: Restoration of squamous mucosa after ablation of Barrett's esophagus epithelium. Gastroenterology 104:1686–1691, 1993Google Scholar
  8. 8.
    Jones R, Barnham CP, Hardwick R, Shepherd N, et al: Regression of columnar-lined esophagus following KTP laser ablation with acid suppression. Gastroenterology 110:A537, 1996Google Scholar
  9. 9.
    Laukka MA, Wang KK: Initial results using low dose photodynamic therapy in the treatment of Barrett's esophagus. Gastrointest Endosc 42:59–63, 1994Google Scholar
  10. 10.
    Wang KK, Geller A, Gutta K, Laukka M, et al: Photodynamic therapy in the treatment of Barrett's esophagus. Gastroenterology 110:A290, 1996Google Scholar
  11. 11.
    Overholt B, Panjehpour M, Tefftellar E, Rose M: Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus. Gastrointest Endosc 39:73–76, 1993Google Scholar
  12. 12.
    Overholt BF, Panhehpour M: Barrett's esophagus: Photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer. Gastrointest Endosc 42:64–70, 1995Google Scholar
  13. 13.
    Overholt BF, Pannehpour M: Photodynamic therapy for Barrett's esophagus: Clinical update. Am J Gastroenterol 91:1719–1723, 1996Google Scholar
  14. 14.
    Barr H, Shepherd NA, Roberts DJH, Tan WC, et al: Eradication of high grade dysplasia in columnar lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 348:584–585, 1996Google Scholar
  15. 15.
    Sampliner RE, Fennerty MB, Garewal HS: Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: Preliminary results. Gastrointest Endosc 44:523–525, 1996Google Scholar
  16. 16.
    Aronchick CA, Lipshutz WH, Wright SH, DuFrayne FJ, et al: P9 bicap cautery converts Barrett's epithelium to squamous mucosa. Am J Gastroenterol 90:A1554(3), 1995Google Scholar
  17. 17.
    Schlesinger PK: Diminished esophageal acid sensitivity in patients with advanced esophagitis. Gastroenterology 92:A1622, 1987Google Scholar
  18. 18.
    Johnson DA, Winters C, Spurling TJ, et al: Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 9:23–27, 1987Google Scholar
  19. 19.
    Trimble KC, Pryde A, Heading RC: Lowered esophageal sensory threshold in patients with symptomatic but not excess gastroesophageal reflux disease: Evidence for a spectrum of visceral sensitivity in GORD. Gut 37:7–12, 1995Google Scholar
  20. 20.
    Stein HJ, Hoeft S, DeMeester TR: Functional foregut abnormalities in Barrett's esophagus. J Thorac Cardiovasc Surg 105:107–111, 1993Google Scholar
  21. 21.
    Johnson LF, DeMeester TR: Twenty-four hour pH monitoring of the distal esophagus. Am J Gastroenterol 62:325–332, 1974Google Scholar
  22. 22.
    Hetzel DJ, Dent J, Reed WD, Marieluala FM, et al: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903–912, 1988Google Scholar
  23. 23.
    Gracely RH, McGrath P, Dunber R: Ratio scales of sensory and affective verbal pain descriptors. Pain 5:5–18, 1978Google Scholar
  24. 24.
    Smith JL, Opekun AR, Larkai E, Graham DY: Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 96:683–689, 1989Google Scholar
  25. 25.
    Fass R, Higa L, Kodner A, Naliboff B, et al: Chronic mucosal inflammation of the esophagus in gastroesophageal reflux disease (GERD) is not associated with mechanical hyperalgesia. Gastroenterology 110:A662, 1996Google Scholar
  26. 26.
    Sampliner RE: Ablative therapies for the columnar lined esophagus. Gastroenterol Clin North Am 1997 (in press)Google Scholar
  27. 27.
    Mayer EA, Gebhart GF: Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 107:271–293, 1994Google Scholar
  28. 28.
    Campbell JN, Raja SN, Cohen RH, Manning DC, et al: Peripheral neural mechanisms of nociception. In Textbook of Pain. RD Wall, R Melzack (eds). New York, Churchill Livingstone, 1989, pp 22–45Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • Ronnie Fass
  • John M. Yalam
  • Lisa Camargo
  • Cindy Johnson
  • Harinder S. Garewal
  • Richard E. Sampliner

There are no affiliations available

Personalised recommendations